Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Common Equity (2016 - 2025)

Spero Therapeutics filings provide 10 years of Common Equity readings, the most recent being $59.0 million for Q4 2025.

  • On a quarterly basis, Common Equity rose 27.96% to $59.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $59.0 million, a 27.96% increase, with the full-year FY2025 number at $59.0 million, up 27.96% from a year prior.
  • Common Equity hit $59.0 million in Q4 2025 for Spero Therapeutics, up from $26.5 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $118.8 million in Q1 2021 to a low of $26.5 million in Q3 2025.
  • Median Common Equity over the past 5 years was $63.7 million (2022), compared with a mean of $66.8 million.
  • Biggest five-year swings in Common Equity: crashed 70.97% in 2022 and later surged 65.33% in 2023.
  • Spero Therapeutics' Common Equity stood at $88.3 million in 2021, then decreased by 13.99% to $75.9 million in 2022, then surged by 40.77% to $106.9 million in 2023, then plummeted by 56.85% to $46.1 million in 2024, then increased by 27.96% to $59.0 million in 2025.
  • The last three reported values for Common Equity were $59.0 million (Q4 2025), $26.5 million (Q3 2025), and $32.8 million (Q2 2025) per Business Quant data.